Higher Tissue Levels of Thymidylate Synthase Determined by ELISA Are Associated with Poor Prognosis of Patients with Lung Cancer
Thymidylate synthase (TS) is essential in thymidylate biosynthesis and DNA replication. Dihydropyrimidine dehydrogenase (DPD) is a rate-limiting enzyme in pyrimidine catabolism and is important in catabolism of 5-fluorouracil (5-FU). The significance of TS and DPD expressed in lung cancer remains controversial. Here we analyzed the relationship between TS and DPD expression and clinicopathological features of lung cancer. Enzyme-linked immunosorbent assays (ELISAs) were used to measure TS and DPD levels in paired tumor and non-tumor lung tissues obtained from 168 patients (107 adenocarcinomas, 39 squamous cell carcinomas, and 22 others), who had operations at the Shinshu University Hospital from 2004 to 2007 and were followed up for a median of 57.0 months. TS and DPD expression levels were higher in tumor tissues, and TS expression levels were significantly lower in adenocarcinomas than those in other subtypes. In addition, patients with low TS levels survived longer compared with patents with high TS levels. By contrast, DPD expression levels were not correlated with overall patient survival. Importantly, patients with low TS and DPD levels exhibited significantly prolonged survival than those with high TS and DPD. Among the 168 patients, 59 patients were treated with tegafur-uracil (UFT), a DPD-inhibitory fluoropyrimidine, and the UFT-treated patients with high TS and high DPD levels showed worst prognosis. Our study demonstrates a significant correlation between low TS expression levels and long-term prognosis of patients with lung cancer. Thus, ELISA is a clinically useful method to measure TS and DPD expression in lung cancer tissues.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:242 |
---|---|
Enthalten in: |
The Tohoku journal of experimental medicine - 242(2017), 4 vom: 10. Aug., Seite 303-316 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Shiina, Takayuki [VerfasserIn] |
---|
Links: |
---|
Themen: |
1548R74NSZ |
---|
Anmerkungen: |
Date Completed 14.05.2018 Date Revised 14.05.2018 published: Print Citation Status MEDLINE |
---|
doi: |
10.1620/tjem.242.303 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM275084434 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM275084434 | ||
003 | DE-627 | ||
005 | 20231225004900.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2017 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1620/tjem.242.303 |2 doi | |
028 | 5 | 2 | |a pubmed24n0916.xml |
035 | |a (DE-627)NLM275084434 | ||
035 | |a (NLM)28835573 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Shiina, Takayuki |e verfasserin |4 aut | |
245 | 1 | 0 | |a Higher Tissue Levels of Thymidylate Synthase Determined by ELISA Are Associated with Poor Prognosis of Patients with Lung Cancer |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.05.2018 | ||
500 | |a Date Revised 14.05.2018 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Thymidylate synthase (TS) is essential in thymidylate biosynthesis and DNA replication. Dihydropyrimidine dehydrogenase (DPD) is a rate-limiting enzyme in pyrimidine catabolism and is important in catabolism of 5-fluorouracil (5-FU). The significance of TS and DPD expressed in lung cancer remains controversial. Here we analyzed the relationship between TS and DPD expression and clinicopathological features of lung cancer. Enzyme-linked immunosorbent assays (ELISAs) were used to measure TS and DPD levels in paired tumor and non-tumor lung tissues obtained from 168 patients (107 adenocarcinomas, 39 squamous cell carcinomas, and 22 others), who had operations at the Shinshu University Hospital from 2004 to 2007 and were followed up for a median of 57.0 months. TS and DPD expression levels were higher in tumor tissues, and TS expression levels were significantly lower in adenocarcinomas than those in other subtypes. In addition, patients with low TS levels survived longer compared with patents with high TS levels. By contrast, DPD expression levels were not correlated with overall patient survival. Importantly, patients with low TS and DPD levels exhibited significantly prolonged survival than those with high TS and DPD. Among the 168 patients, 59 patients were treated with tegafur-uracil (UFT), a DPD-inhibitory fluoropyrimidine, and the UFT-treated patients with high TS and high DPD levels showed worst prognosis. Our study demonstrates a significant correlation between low TS expression levels and long-term prognosis of patients with lung cancer. Thus, ELISA is a clinically useful method to measure TS and DPD expression in lung cancer tissues | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a ELISA | |
650 | 4 | |a dihydropyrimidine dehydrogenase | |
650 | 4 | |a fluoropyrimidines | |
650 | 4 | |a lung cancer | |
650 | 4 | |a thymidylate synthase | |
650 | 7 | |a Tegafur |2 NLM | |
650 | 7 | |a 1548R74NSZ |2 NLM | |
650 | 7 | |a Dihydrouracil Dehydrogenase (NADP) |2 NLM | |
650 | 7 | |a EC 1.3.1.2 |2 NLM | |
650 | 7 | |a Thymidylate Synthase |2 NLM | |
650 | 7 | |a EC 2.1.1.45 |2 NLM | |
700 | 1 | |a Saito, Gaku |e verfasserin |4 aut | |
700 | 1 | |a Sakaizawa, Takao |e verfasserin |4 aut | |
700 | 1 | |a Agatsuma, Hiroyuki |e verfasserin |4 aut | |
700 | 1 | |a Tominaga, Yoshiaki |e verfasserin |4 aut | |
700 | 1 | |a Hyogotani, Akira |e verfasserin |4 aut | |
700 | 1 | |a Hamanaka, Kazutoshi |e verfasserin |4 aut | |
700 | 1 | |a Toishi, Masayuki |e verfasserin |4 aut | |
700 | 1 | |a Takasuna, Keiichiro |e verfasserin |4 aut | |
700 | 1 | |a Kondo, Ryoichi |e verfasserin |4 aut | |
700 | 1 | |a Yoshida, Kazuo |e verfasserin |4 aut | |
700 | 1 | |a Ito, Ken-Ichi |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Tohoku journal of experimental medicine |d 1950 |g 242(2017), 4 vom: 10. Aug., Seite 303-316 |w (DE-627)NLM000023612 |x 1349-3329 |7 nnns |
773 | 1 | 8 | |g volume:242 |g year:2017 |g number:4 |g day:10 |g month:08 |g pages:303-316 |
856 | 4 | 0 | |u http://dx.doi.org/10.1620/tjem.242.303 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 242 |j 2017 |e 4 |b 10 |c 08 |h 303-316 |